- The Best Lawyers in America named Pinar to its Ones to Watch list for Technology Law (2020)
Pinar advises on technology-based commercial transactions, including intellectual property acquisitions and licensing, patent prosecution, patent portfolio analysis and intellectual property due diligence for clients in the life sciences and high technology industries. She also advises clients on IP matters associated with corporate transactions. Pinar combines a deep scientific and technical background with thorough legal analysis to counsel clients in IP matters presenting novel legal challenges that frequently arise from cutting edge emerging technologies.
Pinar’s representative transactions include development, collaboration, license, supply, and service agreements and software agreements, including click-through online agreements and privacy policies. In her patent work, Pinar handles complex cross-over technologies touching on biotechnology.
Prior to joining Fenwick, Pinar was a patent agent in the IP counseling and patents group at an Am Law 100 firm in Palo Alto. Since 2011, she has managed patent portfolios of biotechnology companies in a wide range of technical fields, including gene sequencing, gene synthesis, microfluidics, gene therapy, personalized medicine, bioinformatics, and machine learning.
Pinar received her J.D. from Stanford Law School, her Ph.D. in biophysics from the University of California San Francisco and her B.S. in molecular biology and genetics and physics from Bogazici University, as class valedictorian. While at Stanford Law School, she was the recipient of the Gerald Gunther Prize for Outstanding Performance in Intellectual Property and the John Hart Ely Prize for Outstanding Performance in Intellectual Property and Antitrust Law. At UCSF, she was the recipient of Howard Hughes Medical Institute Predoctoral Fellowship.
- “Avoiding Loss of Title to Inventions Made Under Federal Funding as New Bayh-Dole Requirements Affect Patent Rights,” Fenwick & West, August 2020
- “Digital Health Companies May Find a Faster Path to Market Under the FDA’s Digital Health Plan,” Life Sciences Legal Insights Blog, August 2017
- “Transactions Triggering the 35 USC §102 On-Sale Bar,” Intellectual Property Strategist, July 2017
Education & Admissions
J.D., Stanford Law School
University of California, San Francisco
B.S., Molecular Biology & Genetics and Physics
Admitted to practice in California
Registered to practice before the U.S. Patent and Trademark Office